Contraceptive patch delivers hormone via microneedles

Wednesday, 20 November, 2019

Contraceptive patch delivers hormone via microneedles

US scientists have developed a contraceptive patch with a novel effervescent backing that separates from an array of microneedles after one minute, leaving the needles to slowly biodegrade as they release the hormone levonorgestrel beneath the skin’s surface over the course of a month. Their work has been described in the journal Science Advances.

Currently available long-acting hormonal contraceptives can protect women from unplanned pregnancies for years, but they are invasive and must be administered by trained healthcare professionals.

“We developed this effervescent microneedle patch to increase access to long-acting contraception by enabling women to easily self-administer the drug without the need for a healthcare provider,” said study co-author Mark Prausnitz, from the Georgia Institute of Technology. The researchers designed the patch with contraceptive-releasing microneedles made from poly (lactic-co-glycolic) acid, a copolymer used in many pharmaceutical and medical products.

Tests in rats indicate that the microneedles deliver the necessary birth control dose for more than 30 days, suggesting a patch could provide a simple, discrete alternative to pills, subcutaneous implants and intrauterine devices (IUDs). In addition to demonstrating the efficacy of the patch in rats, the researchers found it could be easily and painlessly applied when its application was evaluated on 10 women of reproductive age.

Study participants all stated they would prefer the monthly patch to a monthly birth control injection, with 90% saying they would also prefer it to daily pills and 60% saying they would prefer to administer the patch themselves. Skin redness usually disappeared within an hour and pain, if present at all, was much less than that experienced with an injection.

The authors have not yet tested the patch’s efficacy as a contraceptive in humans.

Commenting on the research, Dr Alex Polyakov from The University of Melbourne noted that levonorgestrel has been used in various preparations for contraception for a number of years since the 1960s and has an excellent safety record and well-studied profile.

“[But] while levonorgestrel has a very good safety and effectiveness record, it has certain side effects that are also well recognised and which are likely to be unaffected by the new administration process,” Dr Polyakov said. “Two of the most bothersome side effects of levonorgestrel-containing long-term contraceptives are irregular bleeding and undesired psychological effects. These are not addressed by the paper.”

Dr Polyakov said the study can only be considered an initial step in developing a novel option to administer levonorgestrel for contraceptive purposes, given that the active patch was not administered to human participants and the pharmacological profile of the device may not to be completely translatable to humans. Should further research prove successful, he anticipates it would be between five and seven years before the patch is available to be used by the general public.

Image credit: ©

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related News

Scientists extend lifespan in roundworms — are humans next?

Caenorhabditis elegans enjoyed a boost in its lifespan when researchers tinkered with a...

Embryos could be susceptible to COVID-19

Genes that are thought to play a role in how the SARS-CoV-2 virus infects our cells have been...

T cell steroids help tumours suppress the immune system

UK researchers have revealed that tumours can evade the immune system by telling immune cells to...

  • All content Copyright © 2020 Westwick-Farrow Pty Ltd